Semaglutide Weight Management and Cardiovascular Risk Reduction
Oral semaglutide 25 and 50 mg demonstrated statistically
significant and superior reduction in HbA1c compared to 14 mg
0.0
Superior reduction in HbA1c from baseline to 52 weeks
Mean baseline HbA1c: 9.0%
100
Achievement of HbA1c target <7.0% after 52 weeks
Change in HbA1c (%-points)
-0.4
-0.8
-1.2
-1.6
-1.5
% of patients
80
60
60
40
40
-1.9
20
20
-2.0
-2.2
0
-2.4
0 4 8 12 16 20
Time since randomisation (weeks)
26
32
38
44
52 52*
Oral sema 14 mg
Oral sema 25 mg
Oral sema 50 mg
74.2%
59.6%
47.5%
Oral sema 14mg Oral sema 25mg Oral sema 50mg
More participants achieved the HbA₁c target after 52
weeks with oral semaglutide 25 and 50 mg compared
to 14 mg
Note: Observed data are on-treatment. Week 52* is the HbA1c change using the trial product estimand. HbA1c targets are shown with trial product estimand data
Sema: SemaglutideView entire presentation